Related Experiment Video
Updated: Sep 14, 2025
11:02
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
649
Metabolomics in spondylarthritis.
Susann Patschan1, Constantin Remus1, Inga Claus1
1Department of Internal Medicine I, Cardiology, Nephrology and Internal Intensive Medicine, Brandenburg University Hospital, Brandenburg Medical School (Theodor Fontane), Brandenburg an der Havel, Germany.
BMC Rheumatology
|July 23, 2025
Summary
Metabolomics shows promise for diagnosing and predicting spondyloarthropathies (SpA), particularly psoriatic arthritis (PsA). However, current research often focuses on patients with established disease, limiting early detection insights.
Area of Science:
- Rheumatology
- Biochemistry
- Medical Diagnostics
Background:
- Spondyloarthritides (SpA) present clinical challenges in early detection, cardiovascular risk assessment, and disease activity measurement.
- Metabolomics offers a method to quantify numerous small-molecule substances in biological samples for potential diagnostic and prognostic applications.
Purpose of the Study:
- To review the utility of metabolomics in addressing key clinical challenges within spondyloarthropathies.
- To identify the potential of metabolomic approaches for early disease detection, cardiovascular risk stratification, and disease activity monitoring in SpA.
Main Methods:
- A comprehensive literature search was conducted across major scientific databases (PubMed, Web of Science, Cochrane Library, Scopus).
- The review encompassed studies published from 1973 to 2024, focusing on metabolomic analyses in SpA patients.
Main Results:
- Fourteen studies were included, primarily examining patients with established SpA.
- Metabolomic profiles were identified for specific SpA forms, with integrated metabolite and patient data showing promise for assessing psoriatic arthritis (PsA) activity and cardiovascular risk.
Conclusions:
- Metabolomics can aid in discovering novel diagnostic and predictive biomarkers for SpA, especially in PsA.
- A significant limitation across existing studies is the frequent inclusion of patients with advanced disease, hindering insights into early disease stages.
